A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Glioblastoma
Interventions
DRUG

BI 907828 (Brigimadlin)

BI 907828 (Brigimadlin)

Trial Locations (7)

3000

UZ Leuven, Leuven

28041

Hospital Universitario 12 de Octubre, Madrid

32224

Mayo Clinic Cancer Center, Jacksonville

55905

Mayo Clinic, Rochester, Rochester

85054

Mayo Clinic-Arizona, Phoenix

06510

Yale New Haven Hospital, New Haven

08003

Hospital del Mar, Barcelona

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY